TIAA CREF Investment Management’s Intellia Therapeutics NTLA Stock Holding History

TIAA CREF Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	$844K	Sell	49,421 -4,326	-8%	-$64.5K	﹤0.01%	2393
2018 Q4	$734K	Sell	53,747 -1,820	-3%	-$33.8K	﹤0.01%	2410
2018 Q3	$1.59M	Sell	55,567 -5,566	-9%	-$162K	﹤0.01%	2236
2018 Q2	$1.67M	Buy	61,133 +23,986	+65%	+$581K	﹤0.01%	2268
2018 Q1	$783K	Sell	37,147 -3,268	-8%	-$80.4K	﹤0.01%	2548
2017 Q4	$777K	Buy	40,415 +2,076	+5%	+$47.9K	﹤0.01%	2585
2017 Q3	$953K	Sell	38,339 -31,010	-45%	-$584K	﹤0.01%	2538
2017 Q2	$1.11M	Buy	69,349 +49,754	+254%	+$695K	﹤0.01%	2490
2017 Q1	$276K	Sell	19,595 -5,825	-23%	-$78.2K	﹤0.01%	2941
2016 Q4	$333K	Buy	25,420 +4,606	+22%	+$69.2K	﹤0.01%	2957
2016 Q3	$354	Buy	20,814 +689	+3%	+$13.3K	﹤0.01%	2962
2016 Q2	$430K	Buy	+20,125	New	+$535K	﹤0.01%	2929

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OTPPB

Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

TIAA CREF Investment Management's NTLA Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Intellia Therapeutics (NTLA) stake by 8% in Q1 2019, selling an estimated $64.5K and leaving 49,421 shares worth $844K. The position accounts for ﹤0.01% of the portfolio, ranked #2393.

TIAA CREF Investment Management first reported a position in NTLA in Q2 2016 and has held it in 12 quarters since. The position peaked at $1.67M in Q2 2018. 148 funds tracked by Wall St. Rank hold NTLA as of Q1 2019.

TIAA CREF Investment Management held 49,421 shares of Intellia Therapeutics worth $844K as of Q1 2019.
TIAA CREF Investment Management sold 4,326 Intellia Therapeutics shares in Q1 2019, an estimated $64.5K.
Intellia Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2393 holding.
TIAA CREF Investment Management first reported a position in Intellia Therapeutics in Q2 2016 and has held it in 12 quarters since.
TIAA CREF Investment Management's Intellia Therapeutics position peaked at $1.67M in Q2 2018.
148 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.